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Background
Despite the ongoing developments made in modern medical research, cancer
remains the second most common cause of death in the United States [1]. Many
modern treatments, such as radiation therapy and chemotherapy, have numerous
adverse side-effects that may not become evident until months or years after treatment
has ended [2 & 3]. Additionally, there exist few effective treatments for individuals
diagnosed with late-stage cancers. There is a great need for continued research and
development of novel treatment options to facilitate better clinical outcomes of cancer
patients.
Our research of the drug AS1411 aims to address this need for improved cancer
therapeutics. AS1411 is a guanine-rich oligonucleotide optimized for its anti-proliferative
activity of cancer cells. Guanine-rich oligonucleotides (GROs) are short chains of
nucleotides ranging from
approximately 13 to 25
nucleotides and are
predominately composed of
guanine residues [4]. GROs
exhibit a number of properties
that amplify their activity,
including spontaneously
forming G-quadruplex
structures (Figure 1) which
increase the compound’s

Figure 1. An example structure of a G-quadruplex in two
views. (Left) Demonstrates guanine residues forming
hydrogen bonds in the presence of a cation to create a
stable quadruplex. (Right) Illustrates how the backbone of
the oligonucleotide can loop into a stable conformation.
Adapted from Ma et al. 2013 [7].

ability to resist degradation by nucleases [5]. While the exact quadruplex structure of
AS1411is unknown, at least 8 different forms have been detected using a size exclusion
chromatography [6]. Additionally, AS1411 has specificity for cancer cells because it is
capable of binding to nucleolin, a protein that is highly expressed on the surface on
many types of cancer cells [8].
AS1411 has shown promise in both in vitro and in vivo experiments. The GI50
values (the concentration required for 50% growth inhibition) for AS1411 were
remarkably low for almost every tested cancer cell line despite the fact of having little
effect in normal cell lines at similar concentrations [5]. Notably, the compound also
inhibited tumor growth in mouse models despite displaying no toxicity in normal tissues.
These results imply that the anti-proliferative effects of AS1411 selectively target
cancerous cells, unlike standard therapies. In 2003, AS1411 entered into a Phase 1
clinical trial in patients with advanced cancers. During this trial, there were no reports of
severe side-effects and varying degrees of clinical activity. Most patients experienced
disease stabilization, but one patient experienced a complete response; within 11
months [5]. Similar results were later replicated during phase 2 clinical trials, however
the funding company, Antisoma, had to terminate ongoing trials due to the expensive
failure of another drug compound in its pipeline [8]. AS1411 was tested in over 100
patients but only demonstrated strong activity in 7. However, these 7 patients exhibited
strong results including substantial shrinkage and the complete disappearance of
tumors [9]. It was discerned that in order to apply and optimize AS1411, a better
understanding of the mechanism of action was required [8 & 9].

AS1411 is incorporated into the cell by macropinocytosis and that levels of
macropinocytosis and anti-proliferative activity are correlated [10]. In particular, AS1411
induces cell death through a novel pathway known as methuosis, in which the cells
ingest numerous vesicles causing eventual cell lysis [10 & 11]. Methuosis is a novel
nonapoptotic cell death pathway that is characterized by displacement of the cytoplasm
by large fluid-filled vacuoles derived from macropinosomes that ultimately induce cell
lysis. Notably, this pathway involves the hyperstimulation of a number of oncogenic
pathways that ultimately result in cell death [12]. The involvement of these oncogenic
pathways makes methuosis highly promising as a possible target for the treatment of
aggressive or late-stage disease. Although numerous compounds and proteins have
been implicated in the pathway, many aspects of the pathway remain unknown.

Figure 2. Reaction diagram representing the enzymatic activity of HGPRT. The enzyme serves
as a transferase that converts guanine to guanosine monophosphate through the
transference of a phosphoribosyl group from phosphoribosyl pyrophosphate to guanine.
This creates guanosine monophosphate and pyrophosphate as end products.
The accumulation of guanine ribonucleotides can lead to the arrest of the cell
cycle and an inhibition of cellular growth in human cells [13]. Further studies have

suggested that the degradation of GROs (including AS1411) to the monomers of
guanine-based purine compounds (GBPCs) such as guanine, guanosine, and
guanosine monophosphate dictate the anti-proliferative effects in vitro [14]. Additionally,
these anti-proliferative effects are dependent on hypoxanthine-guanine
phosphoribosyltransferase (HGPRT), an enzyme in the purine salvage pathway (Figure
2) [15]. HGPRT is a vital element of the purine salvage pathway and subsequently an
important enzyme for creating the bases that will be sequestered into new DNA [16]. A
loss of HGPRT function in cells makes them unable to recycle certain purines, and this
causes deleterious effects.
This can be seen in the
severely shortened lifespans
of patients affected by Lesch–
Nyhan syndrome, an inherited
disorder caused by an HGPRT
deficiency [17]. My current
hypothesis (Figure 3) posits
that AS1411 acts as a prodrug
for guanine and that the antiproliferative activity should
therefore be dependent upon
the activity of HGPRT. Some
studies in the Bates lab have
indicated that metabolism to

Figure 3. This image demonstrates a hypothesized life cycle
of an AS1411 molecule after binding to a targeted cell. As
indicated, the role of GBPCs and mechanisms of methuosis
progression are not fully understood currently.

guanine plays a role in AS1411 activity [unpublished]; however, more research is
needed to elucidate the mechanism. This project will be combined with our previous
unpublished research with the goal of definitively testing the stated hypothesis.
Ultimately, this knowledge will serve to guide further studies for optimizing AS1411 as a
potential cancer treatment.
Specific Aims
The specific aim for this project was to investigate the possible role of HGPRT in
the anti-proliferative activity of AS1411. If degradation to GBPCs is vital for AS1411
activity, then the loss of HGPRT function should result in a decrease of the compounds
exhibited anti-proliferative effects.
Materials and Methods
Materials
Oligodeoxynucleotides, AS1411 (5′-GGTGGTGGTGGTTGTGGTGGTGGTGG),
and negative control oligonucleotide, CRO (5′-CCTCCTCCTCCTTCTCCTCCTCCTCC)
were purchased in the desalted form from Integrated DNA Technologies (Coralville, IA).
Guanosine and 6-thioguanine were purchased from Sigma (St. Louis, MO). Mouse
monoclonal antibodies, α-tubulin (11H10, Cell Signaling, Danvers, MA) and HGPRT (F1, cat # SC-376938,Santa Cruz Biotech, Dallas, TX) were utilized along with anti-mouse
(sc-2005, Santa Cruz Biotech) and anti-rabbit (sc-2004, Santa Cruz Biotech) antibodies
linked to horseradish peroxidase. Small interfering ribonucleic acids (siRNAs) targeting
human HGPRT, s6887 (5’-GGAUAUGCCCUUGACUAUAtt-3’), s6888 (5’-

AAAUAGUGAUAGAUCCAtt-3’), and Silencer Select Negative Control #1 were
purchased from Life Technologies (Carlsbad, CA).
Cell Lines
A549 cell lines were purchased from the American Type Culture Collection
(ATCC) and grown in Dulbecco's Modified Eagle's medium (DMEM) media (Life
Technologies) supplemented with 1% penicillin/streptomycin (Life Technologies) and
10% fetal bovine serum (Life Technologies) in humidified incubators at 37 °C with 5%
CO2. Cells were plated and incubated overnight to allow for adherence prior to
treatment.
Cell Lysis and Protein Collection
Flasks containing cells were placed on ice and media was removed. Flasks were
then washed with ice-chilled phosphate-buffered saline (PBS, Life Technologies). Cells
were lysed in RIPA buffer [150 mmol/L NaCl, 2 mmol/L EDTA, 50 mmol/L Tris–HCl,
0.25% deoxycholic acid, 1% IGEPAL CA-630 (pH 7.5)] containing protease and
phosphatase inhibitors (Calbiotech, Spring Valley, CA) and collected using a cell
scraper (TPP, Trasadingen, Switzerland) and clarified by centrifugation at 14,000 × g for
10 min at 4 °C. Diluted clarified total cell lysates were analyzed using a Pierce™ BCA
Protein assay kit against a standardized protein concentration curve derived from
known bovine serum albumin (BSA) standards (Fisher Scientific, Waltham, MA).
Protein Analysis by Western Blot

Samples for SDS-PAGE were prepared using 25 μg of protein, 4× loading buffer
containing 10% β-mercaptoethanol, and distilled water to ensure samples of equal
volumes. Samples were resolved using Novex 4 – 20% tris-gylcine gels (Life
Technologies) and then transferred onto polyvinylidine fluoride membranes (Fisher
Scientific) in Tris–glycine transfer buffer (Life Technologies) containing 20% methanol.
Membranes were either blocked with 5% milk in tris-buffered saline containing 0.05%
tween-20 (TBS-T) in TBS-T. The following primary concentrations were used for protein
detection: HGPRT 1:500, and α-tubulin 1:1000. Secondary antibodies were used at a
1:10,000 concentration. Membranes probed with HGPRT primaries were detected using
SuperSignal® West Dura ECL (Fisher Scientific) while α-tubulin was detected using
Pierce® ECL Western Blotting Substrate (Fisher Scientific). Chemiluminescence was
visualized using Amersham Hyperfilm™ (GE Healthcare, Little Chalfont, United
Kingdom).
Cell Proliferation Assay
A549 cells were plated at a density of 1000 cells per well in 96 well plates (TPP)
and incubated overnight to allow for adherence. Cells were treated in triplicate wells
with either oligonucleotide, GBPC, or siRNAs. After treatments of varying duration, MTT
(Sigma) was added in the dark at 1/10th total sample volume, and cells were incubated
for 4 hours. Lysis buffer (10% SDS in 0.01 N HCl) was added at half of the original
sample volume and incubated overnight to ensure complete cell lysis and dissolution of
crystals. Plates were read at 570 nm, and relative absorbance values were exported to
Microsoft Excel® for further analysis [18 & 19]. GraphPad Prism was used to determine
the level of statistical significance by ANOVA and/or t-test.

HGPRT Knockdown via siRNA Transfection for Protein Analysis
A549 cells were transfected with Lipofectamine 2000 (Intivrogen, Carlsbad, CA)
and Opti-MEM ® (Life Technologies) per manufacturer’s protocol. Briefly, cells were
transferred to antibiotic free media for 1 hour before transfection. Cells were then either
transfected with HGPRT siRNAs (s6887 & s6888), or negative control #1 siRNA (Life
Technologies) as seen in Figure 4. After 4 hours, the media containing transfected
reagents was replaced with complete media. Transfected cells were evaluated for
relative proliferation levels using MTT colorimetric assays or lysed for analysis of protein
levels using western blots.

Figure 4. Example plate demonstrating how treatment groups are further divided by
transfection type. Each combination of treatment and transfection is represented by an
average of three individual wells.

Development of Thioguanine-Resistant A549 Cells
A549 cells were grown to ~70% confluency and then transferred to new flasks
containing a 1.5 µM 6-thioguanine (Sigma). After cells grew to confluency, they were
passaged into new flasks with 3 µM increases in concentration of 6-thioguanine. This
was repeated until final concentrations of 6 µM and 15 µM of 6-thioguanine were
established.
Results
Determining Optimal Conditions for AS1411 Anti-Proliferative Effects
In an effort to
identify the
concentration of
AS1411 necessary
for evident antiproliferative activity
in A549 lines, A549
cells were plated at
a density of 1000
cells per well in 96
well plates and
incubated in

Figure 5. Relative proliferation levels of A549 cells treated with
increasing concentrations of AS1411. Results from MTT
colorimetric assay were normalized against a vehicle control. Error
bars represent one standard deviation from the mean.

complete media overnight to allow for adherence. Cells were then treated in triplicate
wells with increasing concentrations of AS1411 and incubated for 72 hours before cell

proliferation assay were performed. Results were normalized to a vehicle control.
Substantial decreases in relative proliferation were observed with a GI50 value of
approximately 1.5 µM AS1411 (Figure 5).
Determining Optimal Conditions for HGPRT Knockdown using siRNAs
A549 cell lines were treated with HGPRT siRNAs to knockdown protein
expression, and subsequent protein samples were analyzed by western blot to confirm
knockdown. Initially, A549 cells were transfected with HGPRT siRNAs (s6887 & s6888),
a negative control siRNA, or left untransfected. After 48 hours, the cells were lysed and

A
.

B
.

Figure 6. (A) Comparisons of HGPRT knockdown using s6887 (#1) & s6888 (#2) siRNA.
Neither sample exhibits any detectable protein expression. Negative control siRNAs and
non-transfected groups demonstrate comparable expression. Loading controls of α-Tubulin
were even in expression across treatment groups. (B) Comparisons of HGPRT knockdown
over 120 hours at 24 hour intervals. HGPRT levels decrease from 24 to 72 hours after
transfection with siRNA s6887 and remains stable through the 120 hour time point.

HGPRT levels were determined by western blot. α-Tubulin was also examined to
ensure equal levels of protein loading. Cells treated by HGPRT siRNAs were found to
decrease HGPRT expression to an undetectable level in comparison to negative control
siRNA or non-transfected samples (Figure 6). Additionally, no detectable difference was
noticed between knockdowns of HGPRT using s6887 or s6888 siRNAs. Additional
samples were transfected and then lysed at 24, 48, 72, 96, and 120 hours in order to
determine the longevity of HGPRT knockdown. Substantial knockdown was found to
occur at 24 hours and increased until 72 hours. From 72 hours to 120, hours protein
levels remained unchanged. The loading control of α-tubulin did not exhibit substantial
changes at any time point.
Analyzing AS1411 Anti-Proliferative Activity in HGPRT Deficient Cells
To determine if the anti-proliferative activity of AS1411 was dependent on
HGPRT function, cells were transfected with HGPRT siRNAs, treated with drug, and
then measured for levels of relative proliferation. A549 cells were transfected with
HGPRT siRNA (s6887), a negative control siRNA, or left untransfected. After 48 hours,
cells were treated with AS1411, CRO, or a water vehicle control for 72 hours before
relative proliferation was measured. Results indicate that HGPRT knockdown caused
no significant variance in AS1411 treatment when compared to controls (Figure 7).
Furthermore, there was no significant variation between the vehicle control groups,
implying that transfection was not inherently toxic to the cells. Additionally, treatment
with 5 μM AS1411 was found to significantly decrease proliferation (p < 0.01) when
compared to CRO groups.

Figure 7. Bar graph
showing relative
proliferation of A549
cells across various
treatment and
transfection types. dH2O
was used as a vehicle
control for
oligonucleotide
treatment. No
statistically significant
difference was observed
between siRNA
transfections in either
the vehicle or AS1411
treatment groups.
AS1411 treatment did
show a significant
decrease in relative
proliferation in contrast
to CRO groups. Results
from MTT colorimetric
assay were normalized
against the vehicle
control. ** indicates a pvalue of < 0.01.
To further investigate if the anti-proliferative activity of AS1411 is dependent on HGPRT
function, transfection parameters were altered to ensure HGPRT knockdown. In the first
variation of the transfection protocol (Figure 8 A), siRNA concentrations were increased
from 20 nM to 40 nM in an attempt to create a more complete knockdown and
determine if results were reproducible. Results from this trial demonstrate a high degree
of similarity to previous findings. No significant variation was found in either the AS1411
or vehicle control, and AS1411 treated cells experienced a significant decrease in
proliferation in comparison to CRO controls (p < 0.05). For the next experiment, the

siRNA transfection time was reduced from 48 to 24 hours to ensure that the plate would
be processed by MTT assay within 120 hours of transfection because previous findings
did not study siRNA knockdown efficacy outside this range (Figure 6, B). Results
(Figure 8, B) from this test had a high degree of similarity to the original findings (Figure
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Figure 8. Variations in transfection protocol to investigate optimal knockdowns of HGPRT.
(A) Bar graph representing relative proliferation with increased siRNA concentrations. Data was
normalized to the untransfected vehicle control. No significant difference was seen between
transfection types in either vehicle (dH2O) or AS1411 treated cells. AS1411 treatment
demonstrated a significant decrease in relative proliferation in contrast to CRO groups, albeit
lower than previous findings (* indicates p < 0.05).
(B) Relative proliferation with decreased overall siRNA transfection time. No significant difference
was seen between transfection types in either vehicle or AS1411 treatment groups. AS1411
treatment did show a significant decrease in relative proliferation in contrast to CRO groups,
similar to the original findings (** indicates p < 0.01).
7). AS1411 and vehicle control treatment groups demonstrated no significant variation

between transfection groups, and AS1411 was shown to have a significant decrease in
proliferation when compared to the corresponding CRO treated cells (p < 0.05).
Determining Optimal Conditions for GBPC Anti-Proliferative Effects in A549 and
MDA-MB-231 Cells
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Figure 9. Comparing guanosine
activity in A549 and MDA-MB231 cells.
(A) Graph showing relative
proliferation of A549 cells
treated with increasing
concentrations of guanosine.
A549 cells show a light response
to guanosine treatment. Error
bars represent one standard
deviation from the mean.
(B) Graph showing relative
proliferation of MDA-MB-231
cells treated with increasing
concentrations of guanosine.
MDA-MB-231 cells show a
lessened response to guanosine
treatment in comparison to
A549 counterparts. Error bars
represent one standard
deviation from the mean.

As mentioned previously, guanine-based purine compounds (GBPCs), such as
guanosine, have been shown to exhibit anti-proliferative effects in vitro [14].
Furthermore, their toxicity appears to be dependent on HGPRT function [15]. To
determine if AS1411 activity is similar to that seen in cells treated with GBPCs, A549
and MDA-MB-231 cells were treated 25 to 400 µM guanosine (Guo) ranging from 25 to
400 µM for 72 hours before cell proliferation assays were performed. A549 cells

demonstrated a dose-dependent response to Guo treatments (Figure 9, A); however,
the anti-proliferative activity was not as substantial as seen with AS1411 at equivalent
concentrations (Figure 4). A549 cells treated with 400 µM Guo demonstrated a relative
proliferation of 60% compared to the control, whereas MDA-MB-231 cells at an identical
concentration only demonstrated a decrease to 80% when compared to the control
(Figure 9).
GBPC Anti-Proliferative Activity in HGPRT Deficient A549 and MDA-MB-231 Cells
After determining the responsiveness of A549 and MDA-MB-231 cell lines to
guanosine, further experiments sought to determine if siRNA knockdown of HGPRT
would decrease the anti-proliferative activity caused by guanosine. Previous literature
has demonstrated that the loss of HGPRT resulted in the loss of anti-proliferative
activity upon exposure to guanosine [15]. If siRNA knockdown of HGPRT decreases the
activity of Guo, then it would suggest that the transfection can effectively reduce
HGPRT activity. However, if transfection is unable to significantly affect anti-proliferative
activity in Guo treatment, then it would suggest that the knockdown is not thorough
enough to fully negate HGPRT enzymatic activity. A549 and MDA-MB-231 cells were
transfected with siRNAs targeting HGPRT, a negative control siRNA, or left
untransfected. After 48 hours, cells were treated with increasing concentrations of Guo,
AS1411, or vehicle for 72 hours before relative proliferation was measured. Results in
A549 cells indicate that cells treated with a vehicle control and transfected with HGPRT

siRNA displayed a decrease in proliferation of 35% in comparison to those transfected
with a negative control siRNA or left untransfected (Figure 10). A dose-dependent
response to Guo treatment was seen across the A549 cells, with 400 µM treatments
reducing relative proliferation by 40-50% depending on transfection type. AS1411
treated groups, however, still exhibited greater drops in proliferation of 60-65%. No
significant difference was seen between transfection types in cells treated with 50 µM,

Figure 10. Bar graph representing relative levels of proliferation in transfected A549 cells
treated with increasing concentrations of guanosine (Guo). Guanosine stock solutions were
prepared in DMEM media and dissolved with minimal amounts of base. DMEM with an
identical concentration of base was used as a vehicle control. Treatment with AS1411 caused
greater decreases in relative proliferation when compared to Guo treatments, and no
significant difference was seen between AS1411 transfection groups. A dose-dependent
response was seen across the guanosine treatment groups from 50 μm to 400 μm. Vehicle
control cells transfected with HGPRT siRNAs demonstrated decreases in relative proliferation
in comparison to negative control siRNAs and non-transfected controls. ** indicates p < 0.01
and * indicates p < 0.05.

100 µM, or 400 µM Guo. Although there was a statistically significant difference seen in
200 µM Guo groups (p = 0.048), replication would be needed to confirm the results.
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Figure 11. Bar graph representing relative levels of proliferation in transfected MDA-MB231 cells treated with increasing concentrations of guanosine (Guo). Cells transfected with
either negative control siRNAs or HGPRT siRNAs demonstrated decreased proliferative in
comparison to non-transfected cells, suggesting possible toxic side-effects from the
transfection itself. Additionally, AS1411 treatments displayed greater levels of antiproliferative activity in comparison to Guo treatments. Unlike in A549 cells, MDA-MB-231
cells did not exhibit a dose-dependent response to Guo treatment. * indicates p < 0.05
and ** indicates p < 0.01.
Results in MDA-MB-231cells did not indicate a strong response to Guo
treatment; however, cells transfected with either HGPRT siRNAs or negative control

siRNAs demonstrated similar levels of relative proliferation (Figure 11). This suggests
possible toxic side-effects from the lipofectamine. Non-transfected cells treated with
Guo consistently demonstrated a decrease in relative proliferation of ~40%. These
outcomes are consistent with the findings of the dose response curve in which A549
cells demonstrated a greater sensitivity to Guo treatment than MDA-MB-231 cells
(Figure 9). Again, cells transfected with HGPRT siRNAs and treated with the vehicle
demonstrated significant decreases in proliferation when compared to non-transfected
cells, suggesting a toxic side effect with the loss of HGPRT function.
Evaluating GBPC and AS1411 Anti-Proliferative Activity in 6-Thioguanine
Resistant Cells
A549 cells were incubated with concentrations of 6-thioguanine (TG) in order to
select for HGPRT mutant cells. Inside the cell, TG acts as an analog to guanine and can
be recycled by HGPRT and then incorporated into the DNA [20]. This incorporation
typically results in strand breakage and eventual cellular death; however, the loss of
HGPRT activity can remove the toxic effects of TG [21]. Based on a previous protocol
[22], HGPRT mutants were selected by increasing treatments of 6-thioguanine and then
treated with increasing concentrations of Guo and AS1411. A549 cells incubated in TG
and wildtype cells were plated for 24 hours, treated with a vehicle control, Guo, or
AS1411 for 72 hours, and then relative proliferation was measured. Although no
significant difference in proliferation was seen in the vehicle controls, TG treated cells
did show increased proliferation across three of the four Guo treatments (50 µM, 100
µM, and 200 µM). Additionally, TG treated cells demonstrated greater levels of

proliferation when treated with AS1411 in comparison to wildtype A549 cells (Figure
12).
N.S.
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*

Figure 12. Bar graph representing relative levels of proliferation in A549 cells and A549 cells
incubated in 15 µM 6-thioguanine (TG). Guanosine stock solutions were prepared in DMEM
media and dissolved with minimal amounts of base. DMEM with an identical concentration
of base was used as a vehicle control. Cells were treated with increasing concentrations of
Guo, AS1411, and a vehicle control. A549 cells and TG cells treated with a vehicle control
did not display a significant difference in proliferation. Alternatively, a significant difference
in proliferation was found in 50 µM, 100 µM, 200 µM, and AS411 treatments. 400 µM
treatments did not show a significant difference in proliferation (p = 0.050). * indicates p <
0.05. ** indicates p < 0.01.

Discussion
Initial experiments were conducted to establish a baseline concentration for
AS1411 anti-proliferative activity in A549 cells and to ensure that HGPRT expression
could be knocked down by transfection with siRNAs. Investigations into the efficacy of
AS1411 treatments in A549 cells demonstrated a GI50 for AS1411 of 1.5 µM (Figure 4).
These findings are congruent with previous findings that cited the GI50 range for AS1411
in A549 cells being approximately 2 µM [23]. Immunoblots of transfected cells were
found to decrease expression of HGPRT when treated with either HGPRT siRNA
(s6887 & s6888). This knockdown effect was seen to begin at 24 hours and last through
120 hours. No difference in protein knockdown was found between the HGPRT siRNAs
s6887 & s6888, so only s6887 was used for transfections. Non-transfected cells were
used as a baseline for HGPRT expression, and cells transfected with a negative control
siRNA were used to gauge whether or not transfection with lipofectamine altered protein
expression. Cells transfected with negative control siRNAs and non-transfected cells
were found to have similar levels of protein expression implying that transfection with
lipofectamine did not alter HGPRT expression. Expression of α-tubulin was measured to
ensure that equal amounts of protein were loaded during the immunoblot process. The
loading controls did not exhibit any irregularities in expression that would discredit
previous findings.
After the GI50 of AS1411 in A549 cells and reliable HGPRT knockdown were
established, A549 cells were transfected and then treated with AS1411 to test if HGPRT
activity was necessary for AS1411 anti-proliferative effects. CRO (cytosine rich
oligonucleotide) treatments in equal concentrations to AS1411 counterparts were used

to determine if oligonucleotide treatment decreased relative proliferation as seen in
previous studies with AS1411 [24]. Additionally, water was used as a vehicle control. In
line with previous findings, AS1411 displayed strong anti-proliferative effects compared
to vehicle and CRO control treatments. Transfected vehicle control treatments did not
exhibit decreased proliferation, suggesting that transfection was not toxic to cells.
Additionally, CRO treatments did not differ significantly to vehicle control treatments
implying that non-specific oligonucleotide treatment was not toxic to cells. Levels of
proliferation did not vary between cells treated with AS1411 and transfected with
HGPRT siRNAs, negative control siRNAs, or left untransfected.
These results could imply multiple outcomes. Since the downregulation of
HGPRT seemingly did not alter AS1411 anti-proliferative activity, it is possible that the
enzyme is not a necessary element for AS1411 activity, possibly because degradation
is not an essential step in the drug pathway. Alternatively, transfections with HGPRT
siRNAs may have knocked down most, but not all of the HGPRT in a cell. In this
scenario, it is possible that a small amount of residual HGPRT was able to preserve the
activity of AS1411.

Additional tests were performed in order to explore the latter possibility. A549
cells were transfected and treated with doubled concentrations of siRNA for comparison
with the previous findings to determine if initial concentrations had produced an
incomplete knockdown. The findings were congruent with previous results. Cells treated
with AS1411 and water did not show any significant change in relative proliferation
across transfection type, and AS1411-treated cells demonstrated lower relative
proliferation when compared to either water or CRO groups (Figure 8 A). These results

suggest that initial concentrations of siRNA were adequate to knockdown further
HGPRT mRNA translation. Additionally, tests were performed in which transfection time
was reduced from 48 to 24 hours to ensure that proliferation was being measured inside
the previously established 120 hour window of HGPRT knockdown. Again, results were
consistent with the original findings. AS1411 treated cells demonstrated decreased
proliferation when compared to CRO or water treated cells. Transfections did not
significantly alter levels of relative proliferation in either the CRO or water groups. These
results indicate that data from initial time points were accurately reflected cellular
proliferation from treatment and knockdown.

Although consistent, this transfection data does not fully answer our previous
question regarding siRNA knockdown of HGPRT. Was there no effect with AS1411
treatment because the compound works by a non-HGPRT dependent mechanism, or
because a residual population of HGPRT exists to preserve anti-proliferative activity?
To answer this, we decided to test our siRNA HGPRT knockdown against GBPC antiproliferative activity. As mentioned previously, GBPCs have antagonistic effects on
cellular growth, and these effects are known to be dependent on HGPRT activity [14 &
15]. If AS1411 and GBPC activity works by an analogous mechanism due to similar
chemical composition and exhibited anti-proliferative effects in cancer cell lines, this
would mean that HGPRT siRNA transfections would affect the anti-proliferative effects
of both compounds in a similar manner. If HGPRT knockdowns are unable to cause a
change in GBPC activity, it would imply that siRNAs were unable to effectively reduce
HGPRT activity and imply that residual pools of HGPRT are preserving AS1411 and
GBPC function. Conversely, if the GBPCs do demonstrate decreases in activity in cells

with decreased levels of HGPRT, it would imply that HGPRT siRNAs are able to
efficiently knockdown HGPRT activity and that AS1411 works by a non-HGPRT
mechanism.

To test this hypothesis, the anti-proliferative effects of GBPCs in our cell lines
needed to be established. A549 and MDA-MB-231 cells were treated with
concentrations of Guo ranging from 25 – 400 µM. These concentrations were chosen in
hopes of developing a dose-dependent response curve and to mimic concentrations of
AS1411 used previously. AS1411 contains approximately 20 guanine bases, meaning
that a 10 µM treatment of AS1411 would be equivalent to a 200 µM treatment of Guo.
A549 and MDA-MB-231 cells both exhibited a response to high concentrations of Guo,
but results were not as drastic as that seen in AS1411 treatments. Additionally, the cells
demonstrated differing levels of response to the treatment, A549 cells treated with 400
µM of Guo decreased in proliferation by approximately 40% when compared to the
vehicle, whereas the decrease in MDA-MB-231 cells was closer to 20% (Figure 9).
Treatments of 200 µM Guo did not decrease proliferation in either cell line to that which
was seen in 10 µM treatments of AS1411 (Figure 5).

With the reactivity of each cell line to GBPCs established, the activity of the Guo
was then tested after transfection with HGPRT siRNAs with the same time points and
protocols as previous AS1411 studies. Treatments of Guo in non-transfected cells
followed previous patterns. A549 cells demonstrated a dose dependent response to
Guo treatment, but MDA-MB-231 cells did not exhibit a strong dose dependent
response. Furthermore, treatment with AS1411 caused greater decreases in

proliferation than Guo, which is consistent with previous dose-response curves in
AS1411 (Figure 5) and Guo (Figure 9). Unfortunately, results in MDA-MB-231 cells
demonstrated decreases in proliferation in both negative control siRNA and HGPRT
siRNA transfections suggesting a toxic side-effect of lipofectamine in MDA-MB-231 cells
at that concentration. Of the eight Guo treatment groups between the two cells types,
seven did not show significant differences between non-transfected, negative control
siRNA transfections, and HGPRT siRNA transfections. One group displayed a
statistically significant difference in proliferation among the transfection types, A549,
200 µM Guo. In the majority of groups, HGPRT knockdown was unable to significantly
alter Guo anti-proliferative activity. Therefore, these experiments have not determined
whether or not the activity of AS1411 is the same as GBPCs.

Expression knockdown via transfected siRNAs operates by engineering siRNAs
with complimentary sequences to the mRNA of interest and delivering them into the cell
via cationic liposomes [25]. Once inside the cell, the siRNAs integrate into the
multiprotein RNAi induced silencing complex (RISC), which can target and degrade the
desired mRNAs [26]. Although this process will knockdown the expression of a
particular protein by a considerable amount, it will not target the preexisting proteins
within the cell. For proteins with short half-lives, this is not problematic for the
experimental procedure; however, some proteins can have half-lives of over 100 hours
[27]. Additionally, the proteins of cells in stressed environments where cellular division
has been slowed or stopped can actually increase their half-lives [28]. HGPRT has a
half-life of over 48 hours [29], which may be extended during periods of stress caused
by treatments of AS1411 or Guo. Previous results demonstrate an incomplete ability to

prevent HGPRT activity, which may be due in part to residual HGPRT inside the cell
that is not silenced by siRNA transfection.
In order to test the activity of these compounds in a HGPRT deficient
environment, A549 cells were incubated in TG in order to select for HGPRT mutant
cells. As mentioned previously, TG is toxic to cells with functioning HGPRT. HGPRT
can transfer a phosphoribosyl group onto TG, allowing it to be incorporated into the
DNA and cause strand breakages [20 & 21]. The employed protocol was based on
previous work [22] that demonstrates how cells can be selected for HGPRT mutations
for mutagenesis studies. After establishing A549 cell lines that could consistently grow
in 15 µM TG, their proliferation in GBPCs and AS1411 were measured against wild type
A549 cells. A statistically significant increase in proliferation was seen across multiple
Guo treatments as well as in AS1411 treatments for cells incubated in 6-thioguanine
over wild type counterparts. Although the mutant cells were not examined by a genomic
assay, their ability to grow and proliferate while being incubated in TG suggests that the
cells did not have a functioning copy of HGPRT. Coupled with the attenuated responses
of HGPRT mutants to GBPC/AS1411 treatment, this suggests that HGPRT activity is
vital for the activity of GBPCs and AS1411. Furthermore, the anti-proliferative activity of
both AS1411 and GBPCs may likely operate by a similar, HGPRT dependent
mechanism. While the results are promising, these experiments have a number of
limitations. A lack of genomic testing of the TG treated cells to confirm mutations in the
HPRT1 gene means that their TG resistance may not have come from a non HGPRTrelated mechanism. Although the vehicle control treatments in TG treated cells and
wildtype cells did not demonstrate significant difference in proliferation, this result could

have been skewed by the large error bar seen in the vehicle treated wildtype cells.
Additionally, the experiment lacked a CRO control to ensure that differences in
proliferation can be attributed to AS1411 and Guo anti-proliferative effects and not
simply to physiological differences in the two cell lines due to TG related stress.
Replication of the experiment with these additional controls would be necessary to
confirm previous results.
Future Directions
Although these results suggest a similar mechanism for AS1411 and GBPCs,
more work is necessary to confirm this hypothesis. Replication of these experiments in
additional cell lines that are more responsive to Guo treatment would help to strengthen
this results. Additionally, genomic testing of TG-incubated A549 cells would be crucial to
confirm mutations in the HPRT1 gene compromised the function of HGPRT. Moreover,
a CRISPR/Cas9 system could be used to create an HGPRT deficient cell line
analogous to HGPRT mutants to further confirm that previous results were due to the
loss of HGPRT function.
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